Nyrada, Inc.ASX: NYR

Xolatryp Demonstrates Cardioprotection in Preclinical Study

· Issued by Nyrada, Inc. via ASX

Filed with ASX ·

Page 1 Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818 Nyrada 21 August 2026 Sydney, Australia Xolatryp® Demonstrates Significant and Sustained Cardioprotection in Preclinical Doxorubicin Study Highlights: • Xolatryp® ...

View Attachment

6ix hasn’t read this filing yet.

Nyrada, Inc. on 6ix

Earlier from Nyrada

Later from Nyrada

All Nyrada news releases